A Dose Finding Study of CycloSam® Combined With External Beam Radiotherapy
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a dose finding study of a novel radiopharmaceutical agent, 153Sm-DOTMP. It will be
studied alone and then in combination with external beam radiotherapy. The study design
includes six cohorts, Levels 1-6. The first three cohorts of participants will receive
153Sm-DOTMP alone, and if this is determined to be safe, subsequent cohorts will receive the
radiopharmaceutical followed by external beam radiotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Albert Einstein College of Medicine David Loeb
Collaborator:
National Cancer Institute (NCI)
Treatments:
Calcium Calcium Carbonate Calcium, Dietary JM 3100 Plerixafor Radiopharmaceuticals